Global Insulinoma Market Size, Share, Forecast Report, 2020-2027

Insulinoma is a rare form of tumour of the beta cells of pancreas resulting in an excessive secretion of insulin, leading to hypoglycaemia. Most insulinomas are benign, however a few metastasize. The symptoms of insulinoma are hypoglycaemia and associated symptoms such as blurred vision, lethargy, diplopia, light headedness, and convulsions, unconsciousness, which can also be life-threatening. Severe hypoglycemia may result in seizures, coma, and permanent neurological damage. Symptoms such as palpitations, tachycardia, sweating, hunger, anxiety etc. are caused by catecholaminergic response to hypoglycaemia triggered by insulinomas.

Insulinomas occur in people between the ages of 40 and 60 and grow slowly. The exact causes of insulinoma are unknown, however, patients with multiple endocrine neplasia type 1 syndrome or von Hippel-Landau syndrome are more at risk. According to a cancer research, 10% of insulinomas are cancerous and approximately 10% of patients diagnosed with insulinoma have more than one tumour. Insulinomas affect between up to five people out of one million each year.

Surgery is the definitive treatment for insulinomas and 90% of patients are cured of the condition. However, surgery can cause diabetes if significant amount of the pancreas are removed. The development of minimal invasive surgery procedures such as laparoscopy has resulted in replacement of open pancreatomy which was once the gold standard of treatment. The market constraints are lack of awareness, misdiagnosis of the disease, risk of surgery, high cost of treatment etc.

The global insulinoma market is expected to reach USD 3.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 3.3 % during the forecast period 2017-2023.
Segments:
The global insulinoma market has been segmented on the basis of type, diagnosis, treatment, and end user.

Based on type, the market has been segmented as benign, and metastasize.

Based on diagnosis, the market has been segmented as blood test, endoscopic ultrasound, Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and others.

Based on treatment, the market has been segmented as surgery, drugs, radiofrequency ablation, chemotherapy and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Key Players in the Global Insulinoma Market
ome of key players profiled in the report are Abcam plc, cironpharma, Pfizer Plc., Entax Medical, Olympus, Boston Scientific Corporation, Medtronic, Cook Medical, Cook Medical, Inc., and others.